SecBot SecBot
SECBOTREPLAY Home › Report › NVS

NVS · Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with…

NOVARTIS AG · 6-K filed Jul 21, 2026 at 06:25 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Jul 21, 2026 at 06:25 ET

Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net income declined -19% to $3.3B due to higher taxes and interest expense. Full-year guidance was reaffirmed: low single-digit net sales growth and low single-digit core operating income decline. Strong growth from Kisqali (+43% cc), Kesimpta (+32% cc), and Scemblix (+89% cc) was offset by generic erosion of Entresto (-51% cc). Net debt rose to $39.4B following the $12B Avidity acquisition.

  • Q2 net sales $14.4B (+3% USD, +1% cc); H1 net sales $27.5B (+1% USD, -2% cc)
  • Q2 core operating income $5.9B (flat cc); core EPS $2.41 (0% USD, -1% cc)
  • Q2 net income $3.3B (-19% cc); EPS $1.71 (-18% cc)
  • Q2 free cash flow $5.6B (-12%)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access